Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06339086
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-01
First Post:
2024-03-18
Brief Title:
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
Sponsor:
Chengdu Brilliant Pharmaceutical Co Ltd
Organization:
Chengdu Brilliant Pharmaceutical Co Ltd
Study Overview
Official Title:
A Multicenter Randomized Open-label and Parallel-controlled Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic in the Treatment of Type 2 Diabetes Subjects With Poor Glycemic Control on Metformin
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic in patients with type 2 diabetes who have poor glycemic control after metformin treatment
Participants will receive either a dose of semaglutide or Ozempic once weekly subcutaneous injection as add-on to metformin for 32 weeks
Researchers will compare the outcomes of semaglutide and Ozempic group to see if the efficacy safety pharmacokinetics and immunogenicity of them are similar
Participants will receive either a dose of semaglutide or Ozempic once weekly subcutaneous injection as add-on to metformin for 32 weeks
Researchers will compare the outcomes of semaglutide and Ozempic group to see if the efficacy safety pharmacokinetics and immunogenicity of them are similar
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None